Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-03-01
2011-03-01
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S387900, C530S391100, C530S391700, C424S130100, C424S138100, C424S139100, C424S178100
Reexamination Certificate
active
07897730
ABSTRACT:
This invention relates generally to the preparation of TRAIL receptor-binding agents and uses of the same. In particular, the present invention relates to the preparation of anti-TRAIL receptor antibodies which recognize a common antigen determinant (i.e., epitope) shared by TRAIL-R1 and TRAIL-R2 receptors and their use for TRAIL receptor detection and modulation of TRAIL receptor-mediated function. The TRAIL receptor-binding agents are useful to induce apoptosis in human cancer cells. These targets may either express one or both TRAIL-R1 or TRAIL-R2. The invention provides for the use of the TRAIL receptor-binding agents of the invention in cancer therapy.
REFERENCES:
patent: 5057313 (1991-10-01), Shih et al.
patent: 7115717 (2006-10-01), Mori et al.
patent: 2002/0153509 (2002-10-01), Lynch
patent: 2004/0214235 (2004-10-01), Mori et al.
patent: 2005/0249729 (2005-11-01), Mori et al.
patent: 2005/0282230 (2005-12-01), Ashkenazi et al.
patent: WO 99/37684 (1999-07-01), None
patent: WO 2004085478 (2004-10-01), None
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor binding activities by site directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor alpha: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Rudikoff, Giusti, Cook and Scharff. Single amino acid substitution altering antigen-binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of abbreviated complementarity-determining regions containing specificity determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained by shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Chen, Wiesmann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Buchsbaum, Donald J. et al., Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.Clin. Cancer Res., 9:3731-3741 (Sep. 1, 2003).
Degli-Esposti, Mariapia A. et al., Cloning and Characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family.J. Exp. Med. 186(7):1165-1170 (Oct. 6, 1997).
Ichikawa, Kimisha et al., Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.Nature Medicine, 7(8):954-96- (Aug. 2001).
International Search Report and Written Opinion, Jul. 19, 2007, for PCT/CN2007/001453.
Kurbanov, Bahtier M. et al., Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).The Journal of Investigative Dermatology, 125:1010-1019 (2005).
Leverkus, Martin et al., TRAIL-induced apoptosis and gene induction in HaCaT Keratinocytes: differential contribution of TRAIL receptors 1 and 2.The Journal of Investigative Dermatology, 121:149-155 (2003).
Liu, Xue-Song et al., Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.Hybridoma and Hybridomics, 22(2):121-125 (2003).
McCarthy, Mary M. et al., Evaluating the Expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer.Clin. Cancer Res., 11(14):5188-5194 (Jun. 15, 2005).
Miller, Kathy et al., Design, construction, and in vitro analyses of multivalent antibodies.The Journal of Immunology, 170:4854-4861 (2003).
Motoki, Kazuhiro et al., Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.Clin. Cancer Res., 11(8):3126-3135 (Apr. 15, 2005).
Muhlenbeck, Frank et al., The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation.The Journal of Biological Chemistry, 275(41):32208-32213 (Oct. 13, 2000).
Vermot-Desroches, Claudine et al., Characterization of monoclonal antibodies directed against trail or trail receptors.Cellular Immunology, 236:86-91 (2005).
Yuanfang et al., Analysis of TRAIL receptor expression using anti-TRAIL death receptor-5 monoclonal antibodies.Chinese Medical Journal, 116(6):947-950 (2003).
Examiner's First Report for Australian Pat. Appln. No. 2007247688, dated Jun. 18, 2010.
Supplementary European Search Report and Search Opinion for EPO Pat. Appln. No. 07721026.8, dated May 19, 2010.
Jia Xianzhao
Shen Enyun
Song Yang
Yu Zheng
Zhou Min
Beijing Cotimes Biotech Ltd.
Foley & Lardner LLP
Gussow Anne M.
LandOfFree
TRAIL receptor-binding agents and uses of the same does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TRAIL receptor-binding agents and uses of the same, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TRAIL receptor-binding agents and uses of the same will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2779851